Infectious Disease Advisor news story
Long-acting injectable cabotegravir plus rilpivirine (CAB+RPV) maintains virologic suppression among individuals with HIV and obesity, with effectiveness and tolerability comparable to individuals without obesity. These findings suggest obesity may not meaningfully compromise outcomes with this injectable antiretroviral therapy regimen, according to study results published in HIV Medicine.
Investigators conducted an ambispective, multicenter real-world cohort study including adults with virologically suppressed HIV-1 infection who transitioned to injectable CAB+RPV between June 2023 and December 2024. Of 3203 individuals initially recruited, 3146 had suppressed viral loads at baseline and were included in the analysis. BMI data were reported for 2736 participants, including 362 (11.5%) classified as having obesity (BMI ≥30 kg/m²).
Read the full news story here.
/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Source : Infectious Disease Advisor
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.